By
AmyT on
September 16, 2010
Calibra Medical’s new insulin “patch pen,” brand-named Finesse, has been approved by the FDA and performed extremely well in recent patient studies. The product could be a huge hit — if the company can secure the financial backing it needs to get production off the ground, according to the physician leading their research charge.
So let’s start at the beginning here: What the heck is a “patch pen,” anyway? That’s what I wanted to know.…
Read more »
By
AmyT on
August 24, 2010
I could call today’s guest post a “straggler” from my Summer Reading series, but that might downplay its impact. Good things take time, as noted today by Samantha Katz, who along with a fellow graduate student at Northwestern University, won the the $10K Grand Prize in the 2009 DiabetesMine Design Challenge.
She was subsequently hired by Medtronic as a Global Product Manager for their evolving insulin pump systems (! – and she served as a…
Read more »
{Note: this is second in a two-part series aimed not only at patients, but those in the Pharma industry as well.}
I was interviewed the other day for an upcoming story about Sanofi-Aventis’ new strategy to not just offer individual diabetes products, but become a “full diabetes management vendor.” They are not alone. Medtronic, Roche, Bayer, Abbott and others are among the big industry players talking about more of a “systems approach” to diabetes as…
Read more »
{Note: this two-part series is aimed as much at Pharma as at patients. If you work in the industry, please read.}
If the emphasis among diabetes systems vendors last year at the annual American Diabetes Association Conference was “data visualization,” then this year’s was “data interpretation.“ I am 100% more enthused about the latter, and I’ll tell you why.
It seemed that last year, all the big players — J&J, Medtronic, Abbott Diabetes, Roche, and…
Read more »
